Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 23.4.2018 | EN | Official Journal of the European Union | C 142/49 |

---

Judgment of the General Court of 9 March 2018 — Recordati Orphan Drugs v EUIPO — Laboratorios Normon (NORMOSANG)

(Case T-103/17)[(1)](#ntr1-C_2018142EN.01004901-E0001)

((EU trade mark - Opposition proceedings - Application for EU word mark NORMOSANG - Earlier national word mark NORMON - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 (now Article 8(1)(b) of Regulation (EU) 2017/1001) - Rule 19(2)(a)(ii) and Rule 20(1) of Regulation (EC) No 2868/95 (now Article 7(2)(a)(ii) and Article 8(1) and (7) of Delegated Regulation (EU) 2017/1430)))

(2018/C 142/65)

Language of the case: English

Parties

Applicant: Recordati Orphan Drugs (Puteaux, France) (represented by: J. Quirin, lawyer)

Defendant: European Union Intellectual Property Office (represented by: A. Lukošiūtė, acting as Agent)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Laboratorios Normon, SA (Tres Cantos, Spain) (represented by: I. Gonzalez-Mogena Gonzalez, lawyer)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 22 November 2016 (Case R 831/2016-5), relating to opposition proceedings between Laboratorios Normon and Recordati Orphan Drugs.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Recordati Orphan Drugs to pay the costs. |

---

[Top](#document1)